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Abstract
Background
Maternal serum concentrations of folate, homocysteine, and vitamin B12 have been associ-
ated with pre-eclampsia. Nevertheless, reported studies involve limited number of cases to
reliably assess the nature of these associations. Our aim was to examine the relation of
these three biomarkers with pre-eclampsia risk in a large Colombian population.
Materials and methods
Design: A case-control study.
Setting: Cases of pre-eclampsia and healthy pregnant controls were recruited at the
time of delivery from eight different Colombian cities between 2000 and 2012.
Population or Sample: 2978 cases and 4096 controls were studied. Maternal serum
concentrations of folate, homocysteine, and vitamin B12 were determined in 1148 (43.6%)
cases and 1300 (31.7%) controls. Also, self-reported folic acid supplementation was
recorded for 2563 (84%) cases and 3155 (84%) controls.
Analysis: Adjusted odds ratios (OR) for pre-eclampsia were estimated for one standard
deviation (1SD) increase in log-transformed biomarkers. Furthermore, we conducted analy-
ses to compare women that reported taking folic acid supplementation for different periods
during pregnancy.
Main Outcomes Measures: Odds ratio for pre-eclampsia.
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Results
After adjusting for potential confounders in logistic regression models, the OR for pre-
eclampsia was 0.80 (95% CI: 0.72, 0.90) for 1SD increase in log-folate, 1.16 (95%CI: 1.05,
1.27) for 1SD increase in log-homocysteine, and 1.10 (95%CI: 0.99, 1.22) for 1SD increase
in log-vitamin B12. No interactions among the biomarkers were identified. Women who self-
reported consumption of folic acid (1 mg/day) throughout their pregnancy had an adjusted
OR for pre-eclampsia of 0.86 (95%CI: 0.67, 1.09) compared to women that reported no con-
sumption of folic acid at any point during pregnancy.
Conclusions
Maternal serum concentrations of folate were associated as a protective factor for pre-
eclampsia while concentrations of homocysteine were associated as a risk factor. No asso-
ciation between maternal vitamin B12 concentrations and preeclampsia was found.
Introduction
Pre-eclampsia is defined as the development of hypertension and proteinuria after the 20th
week of gestation in normotensive women [1], and is considered one of the major causes of
maternal and neonatal morbidity and mortality in low and middle-income countries [2–3].
Although the aetiology of this disorder is poorly understood, a great amount of effort has been
made to identify potential causal risk factors toward preventing the development of pre-
eclampsia [4–7]; nevertheless, they have not yet been translated into largely effective interven-
tions [8–10].
In the last two decades, a number of authors have investigated the effect that maternal con-
centrations of folate, homocysteine, and vitamin B12 may have on the development of pre-
eclampsia [11–12]. Accumulating evidence suggests that hyperhomocysteinemia may be a
cause of the endothelial dysfunction provoked by oxidative stress in pre-eclampsia [13–14].
Homocysteine is an intermediate amino acid that is metabolized into cysteine or methionine.
In the latter, homocysteine requires folate as a co-substrate and vitamin B12 as a cofactor for
the function of involved enzymes such as the methionine synthase enzyme [12]. Low levels of
folate and vitamin B12 have been linked to higher homocysteine levels in the bloodstream,
increasing the risk of pre-eclampsia [14].
Experimental in vitro studies have suggested that high levels of homocysteine induce apo-
ptosis and up-regulation of antiangiogenic factors in human trophoblastic cells obtained from
placentas of healthy pregnant women [15–17]. Interestingly, some of these processes appear to
be suppressed or reverted when trophoblastic cells are treated with folic acid [18–19] In partic-
ular, in vitro studies have shown that human trophoblastic cells obtained from placental tissue
during early pregnancy, promote an increase in extravillous trophoblast invasion and vascular
density (angiogenesis) when cultured in presence of folic acid [19].
Despite these in vitro approaches provide some evidence to the hypothesis that low levels of
folate may lead to pre-eclampsia, observational studies elucidating its impact are deficient [12].
This situation is mainly due to the limited sample size they include as well as the inadequate
control that is performed for potential confounding since most authors only report unadjusted
differences in levels of biomarkers by case control status [12].
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Likewise, further limitations include a lack of power to not only evaluate the association of
biomarkers with pre-eclampsia sub-phenotypes but also determine the shape of this associa-
tion among them and explore possible interactions between folate and homocysteine. In an
effort to overcome these limitations, we investigated the relationship of maternal levels of
three biomarkers (folate, homocysteine, and vitamin B12) with pre-eclampsia using a large
case-control study in pregnant women from Colombia. The understanding gained from this
research will contribute to propose randomised trials that include folic acid supplements to
prevent the development of this disorder.
Materials and methods design
The population included in this work is part of the case-control Genetics and Pre-eclampsia
(GenPE) study conducted in eight different Colombian cities [20]. Participants were young
primigravid women recruited at time of delivery between December 2000 and February 2012.
Pre-eclampsia was defined as blood pressure� 140/90mmHg and proteinuria� 300mg/L in
24-hour specimens or� 2+ dipstick reading in random urine samples, evaluated after 20
weeks of gestation without evidence of any urinary tract infection. Controls were healthy nor-
motensive women without proteinuria, recruited at term (gestation had lasted� 37 weeks).
Also, a control was assigned to a case by assuring that both were from the same recruitment
centre, and if possible, had the same ethnicity and gestational age (±1 week).
GenPE study recruited 3702 cases and 4705 controls. All cases and controls were validated
by an outcome committee before their final inclusion in the study. For this project, women
older than 25 years old (n = 232), women without information on biomarker levels or folic
acid supplementation (n = 675), and women without data on maternal age, gestational age, or
ethnicity (n = 104) were excluded, leaving available information from 2978 cases and 4096
controls for analysis.
Women with a history of autoimmune, metabolic (including diabetes or gestational diabe-
tes), renal, or cardiovascular (including chronic hypertension) disease were excluded of the
study. For subsidiary analyses, pre-eclampsia cases were divided into severe or mild pre-
eclampsia and early- or late-onset pre-eclampsia. Severe pre-eclampsia was defined as blood
pressure >160/110 mmHg and proteinuria >5 g/day or 3+ dipstick, while mild pre-eclampsia
was considered when neither blood pressure nor proteinuria reached these thresholds. Like-
wise, early and late pre-eclampsia were defined as that occurring before or after 34 weeks of
gestation, respectively.
Data collection
Trained personnel conducted a verbal interview to collect clinical and demographic data from
participants through an in-depth questionnaire. Questions related to folic acid supplementa-
tion during pregnancy were included after July 2005 (Fig 1).
Similarly, folate, homocysteine, and vitamin B12 levels were only measured in samples
from participants recruited between December 2000 and November 2008 (Fig 1). Maternal
serum concentrations of folate, homocysteine, and vitamin B12 were determined in 1148
(43.6%) cases and 1300 (31.7%) controls.
To measure biomarker levels, blood samples were taken at the time of recruitment from the
antecubital vein, and their components were separated within 1 hour. Serum was extracted,
frozen, and maintained at –80˚C until performing the assays. Levels of folate, homocysteine,
and vitamin B12 were measured by competitive protein binding chemiluminescent assays fol-
lowing manufacturer’s instructions (IMMULITE; Siemens Medical Solutions Diagnostics).
Pre-eclampsia risk and levels of folate, homocysteine and vitamin B12
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The assay detection ranges were 2–50 μmol/L for homocysteine, 1–24 ng/mL for folate, and
150–1000 pg/mL for vitamin B12.
In addition, assays were conducted by laboratory technicians blinded to participants’ dis-
ease outcome, and case and control samples were randomly distributed across plates to mini-
mize potential assay bias. For quality control purposes, measurements were repeated within 24
hours of the first quantification in randomly selected blood samples as follows: 26 cases and 38
controls in the case of homocysteine, 29 cases and 28 controls in the case of folate, and 21 cases
and 28 controls for vitamin B12.
Ethics approval was obtained prior to participant recruitment by the institutional Ethics
Review Board of Universidad Auto´noma de Bucaramanga, Colombia (Research Ethics Com-
mittee. Act No. 0037/2007. August 29, 2007). All participants signed a written, inform consent.
Participants under age 18 also signed this consent as well as their legal guardian.
Statistical analysis
Data were described using means and standard deviations (SD) for continuous variables and
counts (percentages) for categorical variables. Differences between cases and controls were
evaluated using the t-test and the Kruskal-Wallis test for normally and non-normally distrib-
uted continuous variables, respectively. For discrete variables, the Chi-squared test or the
Fisher exact test were used to compare proportions. This comparison across multiple groups
(i.e. controls, early and late onset and severe PE, was conducted using ANOVA.
Multiple imputations were performed for the observations with incomplete information
related to maternal serum concentrations of folate, homocysteine and vitamin B12 in order to
minimize variations in the estimations. Hence, sample proportions with values outside the
detection limits of the assay were 4% for folate, 3% for homocysteine, and 39% for vitamin B12
(S1 Table). Due to the significant sample proportion obtained below the detection limit for
vitamin B12, multiple imputations were used for these values in order to minimize variations
in the estimations (S1 Appendix), instead of excluding them or performing simple substitu-
tions. The latter has shown to produce altered results when the proportion of values outside
the detection limit is greater than 30% [21–22]. For the quality control samples, Lin’s concor-
dance correlation coefficient [23] was estimated for both measurements, and indicated a
Fig 1. Recruitment period and availability of data for participants in the GenPE study. Each rectangle depicts the total number of
cases and controls with available information for the studied biomarkers and folic acid supplementation. Participants with available
information for both are shown in the overlapping region of the rectangles.
https://doi.org/10.1371/journal.pone.0208137.g001
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complete agreement between them; specifically, 1.0 (95%CI: 0.99, 1.0) for folate, 0.98 (95%CI:
0.97, 0.99) for homocysteine, and 1.0 (95%CI: 1.0, 1.0) for vitamin B12.
Multiple logistic regression was used to evaluate the association between maternal serum
concentrations of folate, homocysteine and vitamin B12, and pre-eclampsia. Crude odds ratios
(OR), 95% confidence intervals (95%CI) and in some cases, standard deviation, were estimated
for each blood marker. Likewise, estimates were adjusted for maternal age, ethnicity, socioeco-
nomic status, multiple pregnancy, smoking, infections during pregnancy, recruitment centre,
and recruitment year. In order to evaluate possible changes of the effect of the biomarkers over
time, interactions between the biomarkers and the year of recruitment (i.e. year of sampling)
were tested in multivariable models the likelihood ratio test (LRT) (comparing nested models
with and without the interaction term). For sub-phenotype analyses, all biomarkers were log-
transformed, standardized, and introduced as continuous variables into adjusted logistic mod-
els that simultaneously estimated the association of each metabolite with the presence of early-
and late-onset pre-eclampsia.
Dose response association. The association of maternal serum concentrations of folate,
homocysteine, and vitamin B12 with pre-eclampsia was assessed in logistic regression models
by introducing the biomarkers as continuous variables after logarithmic transformation (given
their positively-skewed distributions). Restricted cubic spline functions were used to evaluate
the dose response in these models after adjusting for maternal age, gestational age, recruitment
centre, and ethnicity. The spline functions were fitted with three internal knots since this pro-
vided the best fit (S1 Appendix). Departures from linearity were determined through LRT [24]
by comparing models with and without the nonlinear components of the splines.
Association analyses of biomarker levels with pre-eclampsia. Logistic regression models
followed progressive adjustment accounting for different maternal variables such as age,
recruitment centre, recruitment date year-over-year, self-reported ethnicity, multiple preg-
nancy, smoking, socioeconomic position (in two categories), infections during pregnancy, and
gestational age (in weeks). The association of maternal folate levels and pre-eclampsia was also
adjusted by folic acid supplementation in those participants that had information for both (Fig
1). Odds ratios and 95% confidence intervals were reported.
Two potential effect modifications were also examined. The first evaluated the influence
that folate and vitamin B12 levels may have on the association between homocysteine and pre-
eclampsia (interaction previously reported for other diseases) [25]; and the second investigated
the effect that the recruitment period (included as a year-over-year change) may have on the
association of each biomarker with pre-eclampsia. The second method may give some insight
of the consequences related to the introduction of folic acid fortification policies or changes in
pregnancy care over time within the recruitment period. Interaction terms (in a multiplicative
scale) were introduced into the fully adjusted logistic regression models, which were compared
against models without the interaction terms using the LRT (24). A p value lower than 0.05
(p< 0.05) indicated that the nested model with the interaction term had a better fit.
Folic acid supplementation and pre-eclampsia. For participants recruited between July
2005 and February 2012, the association of self-reported folic acid supplementation (1 mg/
day) on pre-eclampsia risk was evaluated using logistic regression models. Dummy indicators
were generated according to the period of supplementation in trimesters [none (reference),
one to two, or three] (S2 Table). The effect of preconception supplementation was not assessed
due to only 0.5% of women reported its consumption. Possible effect modification by recruit-
ment date (included as a year-over-year change) was evaluated with interaction terms tested
by the LRT. The validity of self-reported folic acid supplementation was assessed through look-
ing at differences in biomarker levels by categories of the period of supplementation. Adjusting
the effect of folic acid supplementation by maternal folate was considered unnecessary since it
Pre-eclampsia risk and levels of folate, homocysteine and vitamin B12
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lies in the causal pathway from exposure to outcome, and the design of the study did not allow
evaluating such mediation pathways [26] (S1 Fig).
Sub-analysis by pre-eclampsia early vs. late, mild and severe. As a subsidiary analysis,
the magnitude of the associations for biomarker levels and folic acid supplementation was
evaluated among pre-eclampsia sub-phenotypes in multinomial logistic regression models. In
these analyses, subgroups of pre-eclampsia defined by severity (mild and severe cases) and
time of onset (late and early pre-eclampsia) were compared simultaneously to the control
group. Multinomial logistic regression, an extension of binary logistic regression, was used to
estimate the effect of the same risk factor in two pre-eclampsia categories within a single
model by allowing to include more than two categories of the outcome variable (mutually
exclusive) [27]. Since gestational age defines the presence of early or late pre-eclampsia, it was
removed from the models that evaluate the biomarkers and any pre-eclampsia subgroup in
order to permit the comparison between estimates.
All estimates and 95% confidence intervals (95% CI) were calculated incorporating the
complex design of the sample into the Stata software, version 14 (Stata Corporation, College
Station, TX).
Results
Descriptive analysis
For this study, complete data for 2978 cases and 4096 were included. Sociodemographic and
clinical variables of participants are shown in Table 1. Data revealed that over 90% of the par-
ticipants belonged to a low socioeconomic status, the percentage of multiple pregnancies was
extremely low (1.0% of the total), and there was a very small number of smokers (2.0% of the
total).
From the 2978 cases, 731 were classified as severe pre-eclampsia and 2247 as mild pre-
eclampsia. Similarly, according to time of presentation, 406 cases were early pre-eclampsia,
and 2572 were late pre-eclampsia.
Also, there were 1148 cases and 1300 controls with available data on maternal serum con-
centration for at least one biomarker (1077 cases and 1276 controls with data for all three), and
491 cases and 534 controls with values for at least one biomarker plus information on folic
acid supplementation during pregnancy (Fig 1).
Biomarker levels
Dose response association. For the three biomarkers, the shape of the association was
consistent with a linear relationship between log-transformed values and log-odds of pre-
eclampsia (with the spline models showing no departures from linearity: p = 0.327 for log-
folate, p = 0.450 for log-homocysteine, and p = 0.309 for log-vitamin B12). Log-folate was
inversely associated with pre-eclampsia risk, while a positive linear association was observed
for log-homocysteine and log-vitamin B12. Given that a linear term for log-values was suffi-
cient to summarize the associations under investigation, ORs and 95%CI were reported for 1
standard deviation (SD) change in log-values (Table 2).
Association analyses. All potential confounders included in the logistic models had a
very low percentage of missing values (< 2.5%). The fully-adjusted OR for 1SD increase of log-
folate was 0.80 (95%CI: 0.72, 0.90). The subsidiary analysis by sub-phenotypes of pre-eclamp-
sia showed no strong evidence of these associations to be different from the one obtained for
all pre-eclampsia cases (Fig 2). The sub-sample (56% of total sample size) adjustment for folic
acid supplementation showed a similar point estimate; however, the confidence interval was
wider (OR of 0.88; 95%CI: 0.75, 1.04).
Pre-eclampsia risk and levels of folate, homocysteine and vitamin B12
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In the fully-adjusted model, the OR for an increase of 1SD in log-homocysteine was 1.16
(95%CI: 1.05, 1.27). Estimates were consistent among pre-eclampsia sub-phenotypes defined
by pre-eclampsia severity and time of onset (Fig 2). No interactions were observed with mater-
nal levels of folate (p = 0.191) or vitamin B12 (p = 0.568).
The association between 1SD increase in log-vitamin B12 and pre-eclampsia risk was con-
siderably attenuated from 1.22 (95%CI: 1.12, 1.33) in the age-adjusted model to 1.10 (95%CI:
0.99, 1.22) in a fully-adjusted model. Similar results were obtained after excluding the multiple
Table 1. Baseline characteristics of participants from the GenPE study.
Variable Cases
(n = 2978)
Controls
(n = 4096)
p-value
Maternal age (years), mean (SD) 20.0 18.6 (2.8) <0.001†
Gestational age (weeks), mean (SD) 36.8 (3.3) 39.1 (1.2) <0.001†
Systolic blood pressure (mmHg), mean (SD) 151.5 (13.4) 111.0 (8.7) <0.001†
Diastolic blood pressure (mmHg), mean (SD) 100.1 (10.0) 68.6 (7.4) <0.001†
Folic Acid (ng/mL), mean (SD) 6.4 (4.3) 6.6 (4.1) <0.001†
Homocysteine (μmol/L), mean (SD) 8.4 (4.9) 8.0 (4.8) <0.001†
Vitamin B12 (pg/mL), mean (SD) 287.2 (158.7) 250.4 (127.1) <0.001†
Multiple pregnancies, n (%)
Yes 60 (2.0) 8 (0.2) <0.001†
No 2917 (98.0) 4086 (99.7)
Missing 1 (0.03) 2 (0.1)
Ethnicity, n (%)
White Hispanic 417 (14.2) 538 (13.1) <0.001†
Afro-Caribbean 502 (16.6) 501 (12.2)
Amerindians 45 (1.6) 58 (1.4)
Mixed 2014 (67.7) 2999 (73.2)
Missing 0 (0.0) 0 (0.0)
Socioeconomic status, n (%)
Low (<3) 2658 (88.9) 3646 (89.0) 0.838†
Medium-High (>3) 275 (9.6) 373 (9.1)
Missing 45 (1.6) 77 (1.9)
Smoking during pregnancy, n (%)
Yes 52 (1.8) 84 (2.1) 0.280†
No 2909 (97.7) 3995 (97.5)
Missing 17 (0.6) 17 (0.4)
Infections during pregnancy, n (%)
Yes 2085 (69.6) 2738 (66.9) 0.002†
No 822 (28.1) 1302 (31.8)
Missing 71 (2.3) 56 (1.4)
Folic acid supplementation (at any time), n (%)
Yes 2563 (86.1) 3155 (77.0) 0.829†
No 412 (13.8) 486 (11.8)
Not collected� 3 (0.1) 455 (11.2)
� Data was not collected because a different version of the recruitment questionnaire was used. In this version, the corresponding questions were not included.
† p-values correspond to one-way ANOVA test for continuous variables and Chi-squared test for categorical variables (excluding missing p-values).
SD: standard deviation.
https://doi.org/10.1371/journal.pone.0208137.t001
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imputed data (S3 Table). The estimates from pre-eclampsia sub-phenotypes were largely con-
sistent with those observed for all pre-eclampsia (Fig 2).
On the other hand, there was no evidence of effect modification by year of recruitment for
any of the three biomarkers (p = 0.908 for folate; p = 0.252 for homocysteine; p = 0.874 for
vitamin B12).
Low-dose folic acid supplementation. From the controls with information on folic acid
supplementation (1 mg/day), 86% reported consumption at any time during pregnancy, with
16% reporting supplementation continuously throughout the entire pregnancy and 70%
reporting shorter periods of supplementation. In a sub-sample of 534 controls, we compared
those women who consumed supplements during all pregnancy versus those who took supple-
ments during short periods of pregnancy. Results revealed that women who consumed folic
acid throughout pregnancy had higher maternal serum concentrations of folate [2.3 ng / mL
Table 2. Association dose response of log-folate, log-homocysteine and log-vitamin B12 with pre-eclampsia (adjusted).
Adjustment n Folate
OR (95%CI)
p-value n Homocysteine
OR (95%CI)
p-value n Vitamin B12
OR (95%CI)
p-value
Maternal age (years) 2374 0.91 (0.84, 0.99) � 0.021 2380 1.18 (1.09, 1.28) � <0.001 2374�� 1.22 (1.12, 1.33) � <0.001
Plus recruitment center (eight categories) 2373 0.89 (0.81, 0.98) 0.021 2379 1.15 (1.04, 1.27) � 0.005 2373�� 1.22 (1.11 1.31) � <0.001
Plus recruitment date (years) 2373 0.82 (0.74, 0.91) � <0.001 2379 1.14 (1.04, 1.26) � 0.008 2373�� 1.20 (1.11, 1.28) � <0.001
Plus ethnicity (four categories) 2373 0.82 (0.74, 0.92) � <0.001 2379 1.14 (1.04, 1.26) � 0.008 2373�� 1.19 (1.07, 1.26) � <0.001
Plus low SES (low vs. medium-high) 2344 0.82 (0.73, 0.91) � <0.001 2350 1.15 (1.04, 1.27) � 0.005 2373�� 1.20 (1.12, 1.27) � <0.001
Plus multiparity (yes vs. no) 2330 0.82 (0.73, 0.91) � <0.001 2336 1.15 (1.04, 1.27) � 0.006 2358�� 1.19 (1.10, 1.25) � <0.001
Plus smoking (yes vs. no) 2330 0.82 (0.73, 0.91) � <0.001 2336 1.15 (1.04, 1.27) � 0.006 2358�� 1.19 (1.10, 1.24) � <0.001
Plus infections (yes vs. no) 2374 0.85 (0.77, 0.93) � 0.001 2379 1.18 (1.08, 1.29) � <0.001 2374�� 1.18 (1.54, 1.23) � <0.001
Plus gestational age (weeks) 2270 0.80 (0.72, 0.90) � <0.001 2276 1.16 (1.05, 1.27) � 0.010 2298�� 1.10 (0.99, 1.22) � 0.079
Plus FAS (three categories) 1231 0.88 (0.75, 1.04) � 0.125 1223 1.22 (1.07, 1.40) � 0.003 1209�� 1.09 (0.95, 1.26) � 0.204
�OR reported for 1SD increase in log-transformed values.
��Multiple imputed data for vitamin B12 values.
FAS: folic acid supplementation.
SES: Socioeconomic status
https://doi.org/10.1371/journal.pone.0208137.t002
Fig 2. Sensitivity analysis for the effect of folate, homocysteine and vitamin B12 according to pre-eclampsia (PE) severity and time of onset. The following variables
were included in the full adjustment: age, recruitment centre, recruitment date year-over-year, self-reported ethnicity, multiple pregnancy, smoking, socioeconomic
position (in two categories), infections during pregnancy, and gestational age (in weeks).
https://doi.org/10.1371/journal.pone.0208137.g002
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(95% CI: 0.9, 3.6)] compared to those that took folic acid during short periods. Nevertheless,
the latter had an increase of 1.0 ng / mL (95% CI: 0.4, 1.6) in maternal serum folic acid
concentrations.
Compared to women who did not reported supplementation, participants who reported
use of folic acid supplements for short periods (either one or two trimesters of pregnancy)
showed an adjusted OR of 1.00 (95%CI: 0.84, 1.21), and women that reported use of folic acid
supplements during the entire pregnancy had an adjusted OR for pre-eclampsia of 0.86 (95%
CI: 0.67, 1.09). Subsidiary analysis (comparing supplementation throughout the entire preg-
nancy vs. never supplemented) showed some evidence of a stronger association with early pre-
eclampsia, but for other sub-phenotypes the strength of the association was similar to that
reported for all pre-eclampsia (Fig 3). There was no evidence of effect modification by date of
recruitment (p = 0.185).
Fig 4 shows the exposure-response relationship between serum log-folate and pre-eclamp-
sia risk in the GenPE study. This figure presents the absolute increase in folate levels necessary
to obtain the same Odds Ratio for pre-eclampsia according to the baseline folate levels.
Discussion
This work examined the association of maternal levels of folate, homocysteine, and vitamin
B12 with pre-eclampsia in a large case-control study. Our results showed a possible association
for maternal levels of folate and homocysteine with pre-eclampsia, suggesting that higher folate
levels lower its risk while higher homocysteine levels increase its risk. On the contrary, the
association of vitamin B12 levels with pre-eclampsia was not clear. Subsidiary analysis revealed
that the strength of the association was consistent with that observed for all pre-eclampsia
cases for most of the pre-eclampsia sub-phenotypes, excluding early pre-eclampsia where the
point estimate suggested a stronger association with wider confidence intervals. Also, there
was no evidence of interaction between biomarkers.
Despite we showed a strong association of folate and homocysteine levels with pre-eclamp-
sia, the observed results need a careful interpretation since different factors, such as reverse
causation, may have an influence on them. Nevertheless, several lines of evidence indicate they
are unlikely to entirely explain these observations. To minimize the possibility of confounding,
a thorough adjustment for potential confounders was also conducted, suggesting that the asso-
ciations of folate and homocysteine with preeclampsia are independent of these factors. How-
ever, it is well known that observational studies cannot rule out the presence of residual
confounding.
Given the fact that folate is ingested from diet and obtained from folic acid supplements, a
complementary strategy of analysis was performed to evaluate the influence of folic acid sup-
plementation (1 mg/day) on decreasing the risk of pre-eclampsia in a proportional manner to
its effect on folate levels. This analysis revealed that women reporting supplementation of 1
mg/day of folic acid during the entire pregnancy, which increased folate levels by 2 ng/mL,
had lower odds of pre-eclampsia by 14% (OR 0.86; 95%CI: 0.67, 1.09). Although with some
considerable uncertainty around the point estimate, the observed odds ratio was compatible
with the effect on pre-eclampsia predicted by the model derived in the current study [OR of
0.90 (95%CI 0.86, 0.95)] for an increase of 2 ng/mL in folate levels from a baseline of 5.8 ng/
mL, that corresponded to the mean folate in women without supplementation. Furthermore,
shorter periods of folic acid supplementation was not associated with pre-eclampsia, which is
consistent with results reported on the literature for other populations [28–29].
International guidelines endorse the use of low doses of folic acid supplementation at two
moments during pregnancy: before and up to the 12th week of gestation to prevent the
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development of neural tube defects (from 0.4 mg/day up to 1 mg/day), and after this point
until the end of the pregnancy to avoid anaemia [30–32]. This latter is recommended for
women of low and middle-income countries. In the present study, results strongly suggest a
potential benefit for taking higher doses of folic acid throughout the entire pregnancy to pre-
vent pre-eclampsia. In fact, some authors indicate that the use of folic acid and folic acid-con-
taining supplements offers numerous health advantages for women during pregnancy; for
instance, decreasing the risk for gestational hypertension and pre-eclampsia [33–41].
In Colombia, fortification of wheat flour with folic acid (1.54 mg/Kg) was introduced
around 1997 [42]; unfortunately, there are no reports on the effectiveness of this intervention
at a population level. Furthermore, national guidelines from 2000 recommend folic acid sup-
plementation (1 mg/day) from the time women consider becoming pregnant until the end of
the first trimester to prevent the appearance of neural tube defects on children [42]. The same
daily dose is also advised to be maintained during the rest of the pregnancy until six months
postpartum, along with 60 mg of ferrous sulphate, in order to reduce the prevalence of anae-
mia. It is important to consider the implications for prevention of the linear response, in log-
scale, for maternal folate levels and the odds of pre-eclampsia described in our study. This type
of association implies that higher increments in folate levels are needed in folate-replete popu-
lations in order to obtain the same relative risk reduction, compared to populations with low
average levels.
Extrapolating the results of our log-linear model to other countries, in order to observe a
14% reduction in odds of pre-eclampsia, a trial based in US, where population blood folate
average is 10.5 ng/mL [43], would require an increase in folate levels of 5.8 ng/mL in the inter-
vention arm. Likewise, the needed folate increase for the same risk reduction would be 10.7
ng/mL in Canada, where pregnant women with standard care have average folate levels of 19.2
Fig 3. Sensitivity analysis for the effect of folic acid supplementation according to pre-eclampsia (PE) severity and
time of onset. The following variables were included in the full adjustment: age, recruitment centre, recruitment date
year-over-year, self-reported ethnicity, multiple pregnancy, smoking, socioeconomic position (in two categories),
infections during pregnancy, and gestational age (in weeks).
https://doi.org/10.1371/journal.pone.0208137.g003
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ng/mL [44]. In both cases, the values are two to four-fold higher than those needed in a low
and middle income country with average folate levels around 5 ng/mL (Fig 4). In addition, it
has been shown that proportional increments in folate levels following folic acid supplementa-
tion are greater when pre-treatment concentrations are lower [45]; this means that, for a same
dose comparison, both the increase in folate levels and the expected reduction in pre-eclamp-
sia risk are more likely to be smaller in a population with high folate levels.
Several limitations of the present study merit comment. The biomarkers of interest were
only available for a random subsample of the study since funding for laboratory assays was
insufficient. Similarly, questions related to folic acid supplementation were included in the
questionnaire after the GenPe study had started. As a result, the number of participants with
both biomarker levels and folic acid supplementation information was limited but sufficient to
conduct the analyses.
Regarding the study type (a case-control study), we are unable to examine temporality
between the biomarkers and pre-eclampsia, a constraint that is innate to these types of studies.
Furthermore, despite detailed self-reported information on risk factors and confounders was
available, this information was not validated by linking to medical records. Similarly, the
observed associations for folate and homocysteine could be affected by confounding and/or
reverse causation; however, several lines of evidence indicate that the latter components are
unlikely to entirely explain the findings. To minimize the possibility of confounding, thorough
Fig 4. Exposure-response relationship between serum log-folate and pre-eclampsia risk in the GenPE study. This figure presents the
absolute increase in folate levels necessary to obtain the same Odds Ratio for pre-eclampsia according to the baseline folate levels. The
proportional change in the odds of pre-eclampsia (OR = 0.86) is explained by a proportional increase.
https://doi.org/10.1371/journal.pone.0208137.g004
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adjustment for potential confounders was conducted, suggesting that associations of folate and
homocysteine with pre-eclampsia are independent of these factors; nevertheless, further stud-
ies are needed to explore the causality of the observed associations as well as rule out the pres-
ence of residual confounding.
Conclusion
The results of our study suggest that levels of folate are associated with a protective effect for
pre-eclampsia and levels of homocysteine are associated with a risk factor for pre-eclampsia.
On the contrary, the relationship between levels of vitamin B12 and pre-eclampsia was not
clear. Based on these results, randomised trials in low- and middle-income countries are
needed to evaluate the efficacy and safety of using high doses of folic acid supplementation
during gestational time for pre-eclampsia prevention.
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